Tag Archives: genomics

Emerging Biomarker Companies Redux: BGMD,RGDX,VRML Positioned for Growth

Biomarker Products for Cardiovascular Disease and Cancer This is the third article on Emerging Biomarker Companies. See 11/15/12 Update The synergies between diagnostics and drugs are growing as more treatment options require better data for cost-effective, targeted therapeutics.The development of unique biomarkers has been considered  the “Holy Grail” of innovation in diagnostics but is slow [...]

Leave a comment Continue Reading →

Rayno Life Science Diagnostics and Tools: Big Winners ABAX,ILMN,NEOG,QDEL,TMO

Rayno Diagnostics and Tools-Awaiting Q1 Results Many Rayno Diagnostics and Tools stocks have made new highs recently despite the sector being less frothy than biopharmaceuticals. These stocks are more pinned to financial results and dependent on a steady stream of new products. Important themes are genomics, molecular diagnostics, companion diagnostics and novel assays for infectious [...]

Comments Off Continue Reading →

Is There No End to the Biotech Bull Market?

Biotechnology Sector Q2 2013- At All Time Highs  The BTK and ETFs such as the IBB and XBI hit all time highs on April 2. Of course the current  ramp cannot go on forever because money moves on, speculation ebbs and math intervenes.  We have been picking biotech stocks and forecasting this bull market since [...]

Comments Off Continue Reading →

Rayno Life Sciences Stocks To Watch: ALR, CPHD, QDEL, RGDX- Update 1

Rayno Tools and Diagnostics Stocks Continue Rally Tools and Diagnostic stocks have been the laggards in the Rayno Life Sciences Portfolio compared to biopharmaceutical stocks. Selected stocks within the Rayno Portfolio have perked up and we suggest some rebalancing. Our new long term buy Cepheid (CPHD) is showing accumulation. Underperforming stocks such as Alere (ALR) [...]

Comments Off Continue Reading →

Rayno Life Science Portfolio Dx and Tools: EXAS, ILMN,TMO

Molecular Plays Lead Rayno Dx Focus Stocks Up Illumina (ILMN) rose 4.5% today on “talk” that Roche will increase its buyout offer to $60. Roche told Bloomberg that it does not comment on rumors. Illumina was added to the Rayno Portfolio in 2/2/09 at a price of $29 and the buy was reiterated in 2012 in [...]

Comments Off Continue Reading →

Emerging Biomarker Face-Off: BGMD vs VRML

Vermillion Stock Outperforms BG Medicine Since April 3 On 4/3/12 we posted the biomarker challenge featuring two emerging public companies that have approved diagnostic products. In a few weeks we will have Q2 financial data on these two companies BG Medicine (BGMD) and Vermillion (VRML).  Here is a comparison over 90 days. VRML stock is [...]

Comments Off Continue Reading →